Unsafe
Not Aligned
Patient Risk:
High
Summary
Very low verifiability against the provided FDA label excerpts. All extracted clinical and dosing/side-effect claims for Lantus are unsupported by the supplied label text, and several non-label claims (biosimilar/generic terminology, pricing/patents) are outside typical prescribing information scope. Material safety-critical label elements (e.g., contraindications, boxed warnings, comprehensive hypoglycemia safety context) are not assessed in the provided excerpts.
Category Scores
Accurate Statements
Unsupported Statements
Insulin glargine (Lantus) is a long-acting insulin that is typically injected once daily.
The provided label excerpts do not include Lantus insulin glargine dosing frequency or duration-of-action language; claim is marked absent_from_the_label with no supporting label citation.
Insulin Lantus is administered subcutaneously.
The provided label excerpts do not include Lantus administration route; claim is marked absent_from_the_label with no supporting label citation.
The dosage of Insulin Lantus is individualized based on a patient's blood glucose levels, diet, activity, and other medications.
No Lantus-specific dosage individualization guidance appears in the provided excerpts; claim is marked absent_from_the_label.
Common side effects of Lantus include hypoglycemia (low blood sugar).
While the provided excerpts discuss hypoglycemia with a different insulin product (Insulin Lispro Protamine and Insulin Lispro Mix75/25), they do not establish Lantus-specific adverse reaction statements; claim is marked absent_from_the_label.
Hypoglycemia with Lantus can manifest as dizziness.
No label excerpt provided lists hypoglycemia symptom manifestations such as dizziness for Lantus; claim is marked absent_from_the_label.
Hypoglycemia with Lantus can manifest as sweating.
No label excerpt provided lists hypoglycemia symptom manifestations such as sweating for Lantus; claim is marked absent_from_the_label.
Hypoglycemia with Lantus can manifest as confusion.
No label excerpt provided lists hypoglycemia symptom manifestations such as confusion for Lantus; claim is marked absent_from_the_label.
Hypoglycemia with Lantus can manifest as rapid heartbeat.
No label excerpt provided lists hypoglycemia symptom manifestations such as rapid heartbeat for Lantus; claim is marked absent_from_the_label.
Lantus can cause injection site reactions.
No provided label excerpt addresses Lantus injection site reactions; claim is marked absent_from_the_label.
Lantus can rarely cause allergic reactions.
No provided label excerpt addresses Lantus hypersensitivity/allergic reaction incidence; claim is marked absent_from_the_label.
Blood sugar levels should be monitored closely when using Lantus.
No provided label excerpt includes Lantus monitoring instructions; claim is marked absent_from_the_label.
Biosimilar insulin glargine has been approved and is available in some markets and is often referred to as generic Lantus.
No label excerpts provided address biosimilar approval status or terminology equivalating biosimilars with generics; claim is marked absent_from_the_label and the 'generic' terminology is not label-supported in the provided dataset.
Semglee is a biosimilar to Lantus.
No Semglee label excerpt was provided that states a biosimilar relationship to Lantus; claim is marked absent_from_the_label.
Biosimilars are generally expected to be more affordable than the originator biologic drug.
The provided label excerpts do not discuss pricing/affordability expectations; claim is marked absent_from_the_label.
The availability and pricing of Lantus biosimilars can offer a more affordable alternative to branded Lantus.
No provided label excerpts address pricing or affordability of insulin biosimilars; claim is marked absent_from_the_label.
The primary patents for Lantus expired in the United States around 2015.
No provided label excerpts discuss patents/exclusivity expiration dates; claim is marked absent_from_the_label.
Additional patents and exclusivities may have extended market protection for the branded Lantus for a longer period.
No provided label excerpts discuss patent/exclusivity extensions; claim is marked absent_from_the_label.
The price of Insulin Lantus can vary depending on location, pharmacy, insurance coverage, and whether a generic version is available.
No provided label excerpts discuss pricing determinants or generic availability; claim is marked absent_from_the_label.
A vial of Lantus Solostar can range from approximately $250 to $350 without insurance.
No provided label excerpts contain retail price ranges; claim is marked absent_from_the_label.
The exact retail price of Lantus can differ between pharmacies.
No provided label excerpts contain retail pricing comparisons; claim is marked absent_from_the_label.
Sanofi offers savings cards for Lantus that can lower out-of-pocket expenses for eligible individuals.
No provided label excerpts discuss patient savings cards or manufacturer assistance programs; claim is marked absent_from_the_label.
Some insurance plans offer lower copays for Lantus.
No provided label excerpts discuss insurance copay policies; claim is marked absent_from_the_label.
Insurance coverage affects the final cost of Lantus for patients.
No provided label excerpts discuss insurance coverage/cost effects; claim is marked absent_from_the_label.
Insurance plans differ in copayments and deductibles for prescription medications.
No provided label excerpts discuss insurance plan cost structures; claim is marked absent_from_the_label.
Some insurers may have preferred drugs on their formulary, potentially leading to lower costs for approved alternatives or biosimilars.
No provided label excerpts discuss formulary placement or cost impact of alternatives/biosimilars; claim is marked absent_from_the_label.
Contradictions
Important Omissions
Any Lantus-specific contraindications section content (none assessed/mentioned in the evaluation dataset).
Importance:
High
Boxed warning assessment (if present for the referenced product); not provided in the dataset and thus not evaluated.
Importance:
High
Lantus-specific administration and dosing safety instructions/switching guidance; only Insulin Lispro Protamine/Mix75/25 excerpts were provided under Dosage and Administration.
Importance:
High
Lantus-specific hypoglycemia warnings beyond general statements; provided excerpts discuss hypoglycemia for a different insulin product, not Lantus.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Most Lantus clinical and safety-related claims (route, dosing frequency, individualized titration factors, symptom manifestations, injection site reactions, allergic reactions, monitoring) are unsupported by the supplied label excerpts and appear to be drawn from non-provided information or from a different insulin product context. Pricing/patent/biosimilar terminology claims further reduce label alignment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Claims about insulin glargine (Lantus) are not verifiably supported by the provided FDA label excerpts, which instead reference Insulin Lispro Protamine/Mix75/25. Multiple non-label claims (biosimilar vs generic terminology, patents, pricing, savings cards) are outside prescribing-information scope and are marked unsupported.
Suggested Improvement
Replace Lantus-specific statements with only those explicitly supported by the provided FDA label text for Lantus (including route, dosing frequency, hypoglycemia warnings, monitoring, adverse reactions). Remove or separate non-label content (pricing, patents/exclusivity, manufacturer savings cards, and generic-vs-biosimilar assertions) from label-alignment evaluation.